Human Papillomavirus and Cytomegalovirus Therapeutics Market-Global Industry Analysis and Forecast 2014-2020

Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020

Description : According to a new market report published by Transparency Market Research “Human Papillomavirus and Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” the global human papillomavirus therapeutics market was valued at USD 1.40 billion in 2013 and is expected to grow at a CAGR of 7.7% from 2014 to 2020, to reach an estimated value of USD 2.34 billion in 2020. The global cytomegalovirus therapeutics market was valued at USD 0.87 billion in 2013 and is expected to grow at a CAGR of 1.5% from 2014 to 2020, to reach an estimated value of USD 0.92 billion in 2020.

Human papillomavirus (HPV) and Cytomegalovirus (CMV) are DNA viruses that cause serious health conditions in patients of all ages. HPV is one of the most common sexually transferred viruses causing genital infections and cancers. CMV is an opportunistic pathogen affecting immunocompromised patients; thus transplant and HIV patients are at high risk of acquiring CMV infections. Human papillomaviruses are a group of more than 100 virus strains, of which certain types of viruses lead to warts or papillomas progressing into benign or malignant tumors. More than 40 HPV strains are sexually transferred affecting genital, anal and oral regions. The categorization of HPV strains is done on the basis of risk, i.e. high-risk and low-risk; where high-risk viruses are oncogenic type and low-risk viruses are not associated with cancer. According to CDC, in 2012, an estimated 20 million persons were infected in the U.S., and an estimated 6.2 million new HPV infections were expected to occur annually. HPV infection is common among adolescents and young adults, with prevalence among adolescent girls as high as 64%.

Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics Market Report at :

http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html

Cytomegalovirus infections are usually dormant in healthy individuals; however, the virus stays in the human body for a long time. The virus is easily transmitted through body fluids such as saliva, semen, blood, breast milk and urine. Due to these reasons the virus has spread rapidly through a large population across the globe. Epidemiological studies conducted in various parts of the world report that the seroprevalence of CMV is high in low and middle income countries, and ranges from 50% in certain parts of U.S. and Europe to over 95% in Asia Pacific and South American countries.

Get Free Sample Report Human Papillomavirus and Cytomegalovirus Therapeutics Market :

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3986

Immunomodulators was the largest drug class by revenue share of the HPV therapeutics market in 2013 due to its high efficiency, cost-effectiveness and non-invasive nature of treatment. In the same year, the genital warts segment accounted for the largest market share in HPV therapeutic applications market and is expected to continue to remain a major application of HPV therapeutics, due to its growing prevalence in emerging economies of the world. Ganciclovir and valganciclovir are the first line drugs prescribed for any CMV infection. Valcyte (valganciclovir) by Roche, a prodrug of ganciclovir, is the only branded drug in the market which is expected to lose its exclusivity in March 2015, while pediatric exclusivity will last till September 2015. Thus, ganciclovir and valganciclovir accounted for a major market share in 2013. Retinitis was observed to be the most common complication of CMV infection in HIV patients. Hence, in 2013 retinitis was the largest application segment in CMV therapeutics market.

Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics Market press release at :

http://www.transparencymarketresearch.com/pressrelease/hpv-cmv-therapeutics-market.htm

North American HPV therapeutics market was observed to be the largest market by revenue share due to major driving factors such as rising diagnostic rate, increase in sexually active population, and rising international migration. Moreover, CMV therapeutics market in North America is primarily driven by rise in organ transplant operations, high drug costs and sexually transmitted disease (STD) -triggering sexual lifestyle. Asia-Pacific and South America are anticipated to witness substantial growth in the HPV and CMV therapeutics market. HPV therapeutics market in these geographies will be driven by increasing prevalence of HPV infections, improving economical dynamics, changing sexual lifestyles, and government support to create awareness regarding STDs. CMV therapeutics market in Asia-Pacific and South America is growing due to major market drivers such as high prevalence of HIV infection and increasing number of transplant procedures due to developing economic conditions.

In the HPV therapeutics market, Valeant Pharmaceuticals International, Inc. accounted for a major market share in 2013 with its leading brands such as Aldara (Imiquimod 5%), Zyclara(Imiquimod 3.75%),, Efudex (5-Fluorouracil 5%) and Carac (5-Fluorouracil 0.5%). The other key players in the global HPV therapeutics market are Fougera Pharmaceuticals, Inc., Perrigo Company plc, Taro Pharmaceutical Industries, Ltd., Merck & Co., among others. Roche AG dominated the global CMV therapeutics market in 2013, owing to its Valcyte being the only branded formulation in the market. The other key players in the global CMV therapeutics market are Clinigen Group plc, Gilead Sciences, Ranbaxy Laboratories, Ltd., and Fresenius Kabi USA among others.

The global HPV and CMV therapeutics market is segmented as follows:

HPV Therapeutics Market

• HPV Therapeutics Market, by Drug Class

   

• Immunomodulators

   

• Keratolytic Agents

   

• Antineoplastic Agents

   

• Sinecatechins

HPV Therapeutics Market, by Application

• Genital Warts

   

• Genital Cancer

   

• Epidermodyplasia verruciformis

   

• Oral Papillomas

   

• Others (Oropharyngeal cancer, laryngeal papillomatosis and others)

   

HPV Therapeutics Market, Pipeline Analysis

• Early Stage (Preclinical, Phase I and Phase II) Drug Candidates

   

• Late Stage (Phase III) Drug Candidates.

   

CMV Therapeutics Market

CMV Therapeutics Market, by Major Antiviral Drugs

• Ganciclovir/ Valganciclovir

   

• Foscarnet

   

• Cidofovir

   

CMV Therapeutics Market, by Application

• Retinitis

   

• Pneumonia

   

• Gastrointestinal ulcers

   

• Encephalitis

   

• Others (Mouth ulcers, Diarrhea, Pharyngitis and others)

   

CMV Therapeutics Market, Pipeline Analysis

• Early Stage (Preclinical, Phase I and Phase II) Drug Candidates

   

• Late Stage (Phase III) Drug Candidates

HPV and CMV Therapeutics Market, By Geography

• North America

   

• Europe

   

• Asia-Pacific

   

• South America

   

• Rest of the World (RoW)

NB: The information provided in this press release is for general informational purposes and published on PRnob only.